User login
Chronic lymphocytic leukemia is characterized by significant immune perturbation, including significant impairment of natural killer (NK) cells, which leads to disease complications and reduced effectiveness of treatment.
However, the use of , according to an in vitro study conducted by Maral Hemati, a student researcher at the Semnan (Iran) University of Medical Sciences, and colleagues.
Ms. Hemati and her colleagues obtained bone marrow aspirates (BM) and peripheral blood samples (PB) were from 12 untreated CLL patients (9 men and 3 women) with a median age of 61 years. The cells were cultured in vitro, according to their report in International Immunopharmacology.
The researchers found that the use of recombinant human interleukin-27 (IL-27) stimulated NK cells in the cultured BM and PB cells of CLL patients, based upon assessment using cell surface flow cytometry and a cytotoxicity assay.
Treatment with IL-27 also increased CD69 (a marker for NK cell activity) on NK cells both in BM and PB. In addition, , whereas it did not improve NK cell activity of PB, according to the researchers.
The research was supported by Semnan (Iran) University of Medical Sciences. The authors reported that they had no conflicts of interest.
SOURCE: Hemati M et al. Int Immunopharmacol. 2020;82:doi.org/10.1016/j.intimp.2020.106350.
Chronic lymphocytic leukemia is characterized by significant immune perturbation, including significant impairment of natural killer (NK) cells, which leads to disease complications and reduced effectiveness of treatment.
However, the use of , according to an in vitro study conducted by Maral Hemati, a student researcher at the Semnan (Iran) University of Medical Sciences, and colleagues.
Ms. Hemati and her colleagues obtained bone marrow aspirates (BM) and peripheral blood samples (PB) were from 12 untreated CLL patients (9 men and 3 women) with a median age of 61 years. The cells were cultured in vitro, according to their report in International Immunopharmacology.
The researchers found that the use of recombinant human interleukin-27 (IL-27) stimulated NK cells in the cultured BM and PB cells of CLL patients, based upon assessment using cell surface flow cytometry and a cytotoxicity assay.
Treatment with IL-27 also increased CD69 (a marker for NK cell activity) on NK cells both in BM and PB. In addition, , whereas it did not improve NK cell activity of PB, according to the researchers.
The research was supported by Semnan (Iran) University of Medical Sciences. The authors reported that they had no conflicts of interest.
SOURCE: Hemati M et al. Int Immunopharmacol. 2020;82:doi.org/10.1016/j.intimp.2020.106350.
Chronic lymphocytic leukemia is characterized by significant immune perturbation, including significant impairment of natural killer (NK) cells, which leads to disease complications and reduced effectiveness of treatment.
However, the use of , according to an in vitro study conducted by Maral Hemati, a student researcher at the Semnan (Iran) University of Medical Sciences, and colleagues.
Ms. Hemati and her colleagues obtained bone marrow aspirates (BM) and peripheral blood samples (PB) were from 12 untreated CLL patients (9 men and 3 women) with a median age of 61 years. The cells were cultured in vitro, according to their report in International Immunopharmacology.
The researchers found that the use of recombinant human interleukin-27 (IL-27) stimulated NK cells in the cultured BM and PB cells of CLL patients, based upon assessment using cell surface flow cytometry and a cytotoxicity assay.
Treatment with IL-27 also increased CD69 (a marker for NK cell activity) on NK cells both in BM and PB. In addition, , whereas it did not improve NK cell activity of PB, according to the researchers.
The research was supported by Semnan (Iran) University of Medical Sciences. The authors reported that they had no conflicts of interest.
SOURCE: Hemati M et al. Int Immunopharmacol. 2020;82:doi.org/10.1016/j.intimp.2020.106350.
FROM INTERNATIONAL IMMUNOPHARMACOLOGY